First China Pharmaceutical Group (OTCMKTS:FCPG) is a diversified healthcare and pharmaceutical company engaged in the research, development, manufacturing and sale of a wide range of conventional and traditional Chinese medicinal products. Founded in the early 1990s and headquartered in Hong Kong, the company operates through subsidiaries and joint ventures across mainland China, Southeast Asia and select international markets. Over the years, First China Pharmaceutical Group has established itself as a provider of both prescription pharmaceuticals and consumer health products.
The company’s core business activities include active pharmaceutical ingredient (API) production, formulation manufacturing and distribution of finished dosage forms. Its portfolio encompasses antibiotics, cardiovascular drugs, digestive aids, anti-cancer agents and immunosuppressants. In parallel, the firm maintains dedicated research and development centers focused on innovative drug delivery systems, novel small‐molecule therapeutics and the integration of modern biotech techniques with traditional herbal medicine principles.
In addition to conventional pharmaceuticals, First China Pharmaceutical Group has developed a competitive presence in the botanical and natural health sectors. Key offerings include standardized extracts of Ginkgo biloba, Ganoderma lucidum, American ginseng and other herbal materials, which are incorporated into dietary supplements, functional foods and cosmetic ingredients. The company’s manufacturing facilities comply with Good Manufacturing Practice (GMP) standards, enabling it to serve both domestic and export markets with quality assurance.
First China Pharmaceutical Group’s strategic footprint extends across Greater China, Southeast Asia and North America, supported by a network of distribution partners and licensing agreements. The leadership team comprises seasoned industry executives with backgrounds in pharmaceutical R&D, regulatory affairs and international commercialization. Through a combination of in‐house innovation and collaborative alliances, the company aims to expand its product pipeline and strengthen its position in the global pharmaceutical landscape.
AI Generated. May Contain Errors.
